polylactic acid
Small moleculeexperimental
Polylactic acid, also known as poly(lactic acid) or polylactide (PLA), is a plastic material. As a thermoplastic polyester it has the backbone formula (C3H4O2)n or [–C(CH3)HC(=O)O–]n. PLA is formally obtained by condensation of lactic acid C(CH3)(OH)HCOOH with loss of water. It can also be prepared by ring-opening polymerization of lactide [–C(CH3)HC(=O)O–]2, the cyclic dimer of the basic repeating unit. Often PLA is blended with other polymers. PLA can be biodegradable or long-lasting, depending on the manufacturing process, additives and copolymers. — Wikipedia
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
3
Earliest trial started Jan 1, 2007 (NCT00447551)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPolylactic acid ↗
Also known as
- 70-30 poly-l-lactide-co-d,l-lactide
- atrisorb
- hydrosorb
- pla96
- plla polymer
- poly-96l 4d-lactide
- poly-d,l-lactic acid
- poly(d,l-lactide)
- poly(dl-lactide)
- polylactate
- poly(lactic acid)
- polylactic acid
- poly(lactic acid), (dl)-isomer
- poly(lactic acid), (s)-isomer
- polylactide
- poly(lactide)
- poly(lactide), (l)-isomer
- poly-l-d-lactide
- poly-l-lactic acid
- poly-l-lactic acid
- poly-l-lactic acid
- poly-l-lactide
- poly(l-lactide)
- poly(l-lactide-co-d-lactide)
- poly(l-lactide-co-d,l-lactide)
- polymax
- poly(rac-lactide)
- resomer r104
- resomer r208
- resorb-x
- sr pla96
- sr-pla96
- ticron
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07225348 | Phase 4 | Nov 3, 2025 | Galderma, Skin Care Physicians of Chestnut Hill |
| NCT05913102 | N/A | Sep 28, 2022 | Ajou University |
| NCT03858543 | Early Phase 1 (Phase 1) | Feb 25, 2019 | Galderma, Henry Ford Health System |
| NCT02613481 | N/A | Nov 1, 2015 | Galderma, Yardley Dermatology Associates |
| NCT01422538 | N/A | May 1, 2011 | EpiCentre Park Lane, Ulthera |
| NCT01307865 | Phase 4 | Jan 1, 2011 | Sanofi, Williams Center Plastic Surgery Specialists |
| NCT00447551 | Phase 4 | Jan 1, 2007 | Sanofi |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galderma | For profit | 3 | 0 | 3 | 2015 |
| Sanofi | For profit | 2 | 1 | 1 | 2007 |
| Ajou University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| EpiCentre Park Lane | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Henry Ford Health System | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Skin Care Physicians of Chestnut Hill | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Ulthera | For profit | 1 | 1 | 1 | 2011 |
| Williams Center Plastic Surgery Specialists | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Yardley Dermatology Associates | Academic/Hospital | 1 | 1 | 1 | 2015 |
9 organizations
Page 1 / 1